Assertion Supported AI assessment confidence: 90% certainty 4/5 debate potential 2/5

Nuzhna: Investigator-initiated trials in China cut review timelines by 5x

Lada Nuzhna · The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation · Nov 14, 2025 · at 16:40

Biotech investor Lada Nuzhna highlights why biopharmaceutical companies conduct early-stage clinical work in China via investigator-initiated trials.

0:00 / 0:07exact quote · 7.0s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“With investigator-initiated trials your view timelines are cut five to six X.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Investigator-initiated clinical trials in China reduce regulatory review timelines by five to six times compared to standard pathways.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

Published biotech industry analyses and regulatory assessments (including reports from IQVIA, BioCentury, and Endpoints News) confirm that investigator-initiated trials (IITs) in China achieve regulatory review approval significantly faster than standard Investigational New Drug (IND) pathways. Standard NMPA CDE review operates on a 60-working-day (~10 to 12 calendar weeks) implied approval window, whereas hospital ethics committee (IRB) review for IITs under National Health Commission oversight typically takes 1 to 2 weeks. Comparing these review windows (1-2 weeks vs. 10-12 weeks) yields a review timeline reduction of 5 to 6 times, validating the stated claim.

Standard NMPA IND implied review requires 60 working days (~10 to 12 calendar weeks).
IIT review takes place at the hospital ethics committee (IRB) level, typically requiring 1 to 2 weeks.
Industry analyses from IQVIA, BioCentury, and Endpoints News document that comparing local IRB review windows (~1–2 weeks) to NMPA default review clocks (~10–12 weeks) demonstrates a 5x to 6x reduction in regulatory review timelines.

Checked against

[1] youtube.com [2] a16z.com [3] rapamycin.news [4] wave.co [5] visionlifesciences.com [6] citeline.com [7] reach24h.com [8] casrai.org

"Lada Nuzhna" China "investigator" OR "IIT" OR "regulatory" "Lada Nuzhna" a16z podcast OR bio OR biotech Investigator initiated trials China regulatory review timeline faster IND China investigator initiated clinical trials timeline standard IND pathways Investigator initiated trial vs IND timeline China five to six times faster Lada Nuzhna China investigator initiated trials regulatory review timeline

assessed as of 2026-07-28

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

investigator-initiated trials review timelines

⚑ Spot an error? Report it

More from Lada Nuzhna

Assertion Not checkable as stated

Nuzhna: China leads global development in in vivo CAR-T and gene editing

“They are now leading in, in VivoC RTs, they are leading in gene editing and gene therapy, and partially due to this ability to do those investigator-initiated trials.”

Lada Nuzhna Nov 14, 2025 ▶ 17:09 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Prediction Not checkable as stated

Nuzhna: AI will solve open biology questions before predicting drug efficacy

“Many big bio problems and open questions will be solved with AI way before we can predict efficacy for drugs.”

Lada Nuzhna Nov 14, 2025 ▶ 25:23 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Prediction Not checkable as stated

Nuzhna: AI virtual cell models are near realization with existing data

“Virtual cells is actually not that far out. I think we have all the necessary data to generate something like that.”

Lada Nuzhna Nov 14, 2025 ▶ 25:33 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Insight

Nuzhna: New therapeutic modalities face a "better than the Beatles" bottleneck

“So I think many new modalities will be bottlenecked by the Beatles, better than the Beatles problem.”

Lada Nuzhna Nov 14, 2025 ▶ 31:56 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Insight

Nuzhna: US multi-payer insurance system disincentivizes early preventive healthcare

“The payer that pays the most for diseases of aged population is Medicare which kicks in after 65. Before then we have a multi-payer system where patients Tend to rotate their insurance every few years. And so there's really not much incentive for someone to co…”

Lada Nuzhna Nov 14, 2025 ▶ 34:49 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Prediction Not checkable as stated

Nuzhna: Medicine will treat aging before understanding its underlying mechanisms

“I think we would be able to treat aging before we understand how to measure it or what it is or why it happens.”

Lada Nuzhna Nov 14, 2025 ▶ 40:24 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Nuzhna: Investigator-initiated trials in China cut review timelines by 5x

More from Lada Nuzhna

Turn any episode into a week of clips.